RESEARCHER PROFILE
Professor Kristofer Thurecht, Deputy Director of Research & Senior
Group leader, Australian Institute for Bioengineering and Nanotechnology,
University of Queensland, Australia
Finding better ways of treating cancer, aside from finding a cure, aim to provide a better quality of life for those who suffer from it.
Professor Thurecht’s work focuses on nanomedicine and spans across the Australian Institute for Bioengineering and Nanotechnology and the Centre for Advanced Imaging, at the University of Queensland in Australia.
Professor Thurecht undertook his PhD at the University of Queensland and decided he wanted to go to the University of Nottingham in the UK, where his mentors pushed him into the new field of nanomedicine. On returning to Australia he brought his ideas on nanomedicine back to the University of Queensland, where he works today.
His research focuses on understanding how nanomedicines behave in biological environments using high-end imaging infrastructure, with a focus on radiopharmaceutical research to establish next generation drugs for diseases like cancer.
Nanomedicine research, particularly in the field of cancer treatment, has the potential to revolutionise traditional medicine and improve the quality of life for those suffering from the disease. Radiopharmaceuticals and molecular imaging are revolutionising cancer treatment by providing targeted therapies and precise drug delivery, showing potential for groundbreaking advancements in the field.
Radiopharmaceuticals utilise radiation as a potent therapy for treating diseases, particularly cancer. As Professor Thurecht states, the development of radiopharmaceutical for cancer treatment is a promising and innovative field in nanomedicine.
Outside of research Professor Thurecht enjoys fishing and boating with family on weekends.
You Might also like
-
CASE STUDY High blood pressure and shorter sleep may worsen brain decline
People with high blood pressure who also lack sleep may be at increased risk of reduced cognitive performance and greater brain injury, Monash University research has found.
Published in the Journal of the American Heart Association, researchers assessed whether the combined effect of hypertension and short sleep duration had a negative impact on brain health.
-
Targeting chemotherapy resistance in ovarian cancer patients
Dr Alex Cole, from the Centenary Institute’s Centre for Biomedical AI, is now leading the research focused on developing a new treatment to counteract a protein called follistatin (FST), known for making ovarian cancer cells resistant to chemotherapy.
By employing cutting-edge molecular biology and directed evolution techniques, the project aims to create nanobodies—small, precise molecules—that can block FST. If successful, these nanobodies could enhance the effectiveness of chemotherapy and improve ovarian cancer treatment rates.
-
Risk factors and prevention of respiratory infections and infectious diseases in children
A/Prof Hannah Moore OAM is an infectious disease epidemiologist; Co-Head of the Infectious Disease Epidemiology team within the Wesfarmers Centre of Vaccines and Infectious Diseases at The Kids Research Institute Australia and Associate Professor at the School of Population Health, Curtin University in Western Australia.
A/Prof Moore has been awarded more than $19M in competitive research grants, co-authored more than 140 papers, was TEDxPerth 2018 speaker, recipient of a WA Young Tall Poppy Award (2013) and the WA Premiers Science Early Career Scientist Award (2015). In 2024, she was honoured with a Medal of the Order of Australia for her service to epidemiology as a researcher.